Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Asset disposition
Credit agrmnt [a]
Director departure
Inv. presentation
Quarterly results
Acq. announced

PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/26/2019 8-K Quarterly results
05/21/2019 8-K Asset disposition
05/14/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/07/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Initial Monthly Operating Report"
05/06/2019 8-K Completion of Acquisition or Disposition of Assets
04/19/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amended and Restated Asset Purchase Agreement, by and among Pernix Therapeutics Holdings, Inc. and Currax Holdings LLC"
04/01/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
02/27/2019 8-K Quarterly results
02/19/2019 8-K Quarterly results
11/21/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Mr. John A. Sedor C/O Pernix Thereapeutics Holdings, Inc. 10 North Park Place, Suite 201 Morristown, NJ 07960"
10/31/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/22/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
08/27/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Zohydro® ER with BeadTek®"
08/09/2018 8-K Quarterly results
Docs: "Pernix Therapeutics Reports Second Quarter 2018 Financial Results"
08/01/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Articles Supplementary for 0% Series C Perpetual Convertible Preferred Stock",
"Form of Exchange Agreement, by and among Pernix Therapeutics Holdings, Inc., Deerfield Management L.P. and certain of its affiliates",
"The exchange of approximately $2.7 million aggregate principal amount of Senior Secured Notes by the Exchange Holders for 1,204,739 shares of Common Stock, which includes accrued and unpaid interest on the Senior Secured Notes; and",
"The exchange of approximately $2.7 million aggregate principal amount of Senior Secured Notes by the Exchange Holders for 1,204,739 shares of Common Stock, which includes accrued and unpaid interest on the Senior Secured Notes; and",
"Form of Amendment No. 3 to the ABL Facility, August 1, 2018, by and among Pernix, the guarantors and lenders party thereto and Cantor Fitzgerald Securities, as agent",
"Form of Amendment No. 2 to the Term Facility, by and among PIP DAC, the lenders party thereto and Cantor Fitzgerald Securities, as agent",
"Pernix Therapeutics Announces a Series of Transactions To Strengthen Its Balance Sheet and Improve Financial Flexibility MORRISTOWN, N.J. – August 1, 2018 – Pernix Therapeutics Holdings, Inc. , a specialty pharmaceutical company, announces a series of transactions aimed at strengthening its balance sheet and improving financial flexibility, as described below. Exchange Agreement Pernix entered into exchange agreements with certain holders of Pernix’ s outstanding 12% Senior Secured Notes due 2020 for newly issued shares of common stock and shares of a newly created class of convertible preferred stock, the terms of which are described below . These transactions , are expected to close on August 1, 2018. The Exchange Transactions include:"
07/31/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Pernix Therapeutics Announces Successful Closing of Transaction Regarding Worldwide Rights to Contrave for Weight Loss"
06/22/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss"
05/22/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "PERNIX THERAPEUTICS HOLDINGS, INC. 2017 OMNIBUS INCENTIVE PLAN, AS AMENDED.",
"PERNIX THERAPEUTICS HOLDINGS, INC.",
"Company"), hereby grants a nonqualified stock option to purchase shares of its common stock, par value $0.01 per share , to the Grantee named below . Additional terms and conditions of the grant are set forth on this cover sheet and in the attached Nonqualified Stock Option Agreement (together, the "Agreement"
05/10/2018 8-K Quarterly results
Docs: "Pernix Therapeutics Reports First Quarter 2018 Financial Results"
04/23/2018 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "AMENDMENT NUMBER 1 TO CREDIT AGREEMENT, DATED APRIL 23, 2018",
"Pernix Therapeutics Announces Participation in Lead Bid for Acquisition of Worldwide Rights to Contrave® for Weight Loss"
03/27/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Pernix Therapeutics Announces Return to Market of Zohydro® ER with BeadTek TM 20 mg."
03/08/2018 8-K Quarterly results
Docs: "Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results"
03/05/2018 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "SECOND AMENDMENT TO THE COMPANY'S BYLAWS"
02/28/2018 8-K Other Events
02/20/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company's Subsidiary, Macoven Pharmaceuticals"
02/06/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT AGREEMENT",
"INDEMNIFICATION AGREEMENT",
"Pernix Announces Appointment of Lead Independent Director and Key Management Team Promotion"
01/29/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Pernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro ER"
01/05/2018 8-K Cost Associated with Exit or Disposal Activities
12/29/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "Third Supplemental Indenture, by and among Pernix Therapeutics Holdings, Inc., and U.S. Bank National Association, as trustee"
12/05/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/15/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "THERAPEUTICS HOLDINGS, INC. 2017 OMNIBUS INCENTIVE PLAN"
11/07/2017 8-K Quarterly results
Docs: "Pernix Therapeutics Reports Third Quarter 2017 Financial Results"
10/17/2017 8-K Quarterly results
09/22/2017 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy